GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
71.60
+4.27 (6.34%)
At close: May 23, 2025, 4:00 PM
72.00
+0.40 (0.56%)
After-hours: May 23, 2025, 7:52 PM EDT
Company Description
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
The company is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp.
| Country | United States |
| Founded | 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,000 |
| CEO | Katherine Stueland |
Contact Details
Address: North Tower, 6th Floor Stamford, Connecticut 06902 United States | |
| Phone | 888 729 1206 |
| Website | genedx.com |
Stock Details
| Ticker Symbol | WGS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818331 |
| CUSIP Number | 81663L200 |
| ISIN Number | US81663L2007 |
| Employer ID | 85-1966622 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Katherine A. Stueland | President, Chief Executive Officer and Director |
| Kevin Feeley CPA | Chief Financial Officer |
| Dr. Bryan M. Dechairo Ph.D. | Chief Operating Officer |
| Heidi C. Chen J.D. | Chief Legal Officer |
| Jami Biliboaca | Head of People Strategy |
| Melanie Duquette | Chief Growth Officer |
| Dr. Martin G. Reese Ph.D. | President of Fabric Genomics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G | Filing |
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | SCHEDULE 13D/A | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 29, 2025 | 144 | Filing |
| Apr 29, 2025 | 144 | Filing |